GlaxoSmithKline plc’s stake in the market for next-generation multiple myeloma treatments looks set to be limited by safety and efficacy concerns about its candidate belantamab mafodotin.
The anti-BCMA antibody-drug conjugate (ADC) has shown promise as a monotherapy or combination therapy for relapsed or refractory multiple myeloma,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?